Home › Muscular Dystrophy › NCT05989620

Long-Term Development of Muscular Dystrophy Outcome Assessments

Long-Term Development of Muscular Dystrophy Outcome Assessments (GRASP-01-005)

Who can join

Ages 6 to 50 · All sexes

Inclusion Criteria:

1. Age between 6-50 years at enrollment
2. Clinically affected (defined as weakness on bedside evaluation in a pattern consistent with proximal weakness)
3. Genetic confirmation of a LGMD, DM2, or LOPD
4. FVC above 30% of predicted

Exclusion Criteria:

1. Any other illness that would interfere with the ability to undergo safe testing or would interfere with interpretation of the results in the opinion of the site investigator
2. Participation in a clinical trial receiving an investigational product

About the study

This is a 24-month, observational study of up to 1000 participants with Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy Type 2 (DM2), and late onset Pompe disease (LOPD).

Sponsor: Virginia Commonwealth University · Participants: 1,000 · Started: Oct 18, 2023

Contact the study team

• Jennifer Raymond · Phone: 804-828-6318

Official record on ClinicalTrials.gov — NCT05989620

Locations in the U.S.

Conditions

• Muscular Dystrophy
• Myotonic Dystrophy

From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.